Proxi Biotech ApS: Financial statements 2022
CVR: 39859211
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Proxi Biotech ApS (CVR 39859211) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 411,123 and a net result of DKK -72,371 compared with DKK 2,349 the year before. That is a decrease of 10.7% compared with the year before. Equity in the 2022 report amounted to DKK -78,557. The company had 1 employee in the financial year.
- Gross Profit
- DKK 411,123
- Profit/Loss
- DKK -72,371
- Equity
- DKK -78,557
- Total Assets
- DKK 92,330
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 411 t. | -72 t. | -79 t. | 1 |
| 2021 | - | 461 t. | 2 t. | -6 t. | 1 |
| 2020 | - | 337 t. | 85 t. | -9 t. | 1 |
| 2019 | - | 176 t. | -94 t. | -93 t. | 0 |
Official annual report
Keep an eye on Proxi Biotech ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Proxi Biotech ApS has published its annual report for 2021. Gross profit came to DKK 460,613, and the net result was DKK 2,349.
About Proxi Biotech ApS
Proxi Biotech ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named PrOxi Biotech ApS and PrOxi Biotech IVS. The management consists of Rene Jørgensen and Aria Aminzadeh. The board consists of Sten Verland (chair), Aria Aminzadeh, Paul Jefferson Hargreaves and Per Bo Pedersen Fischer. The company is owned by Aminzadeh Holding ApS, Dr RJ Holding ApS and Century House Holding ApS. The company has 6 employees (2026). In 2025, the company reported a gross profit of DKK -430,820 and a net result of DKK -1,688,504 compared with DKK 426,762 the year before. Equity in the 2025 report amounted to DKK -1,712,625.